Literature DB >> 16491069

Common markers of proliferation.

Michael L Whitfield1, Lacy K George, Gavin D Grant, Charles M Perou.   

Abstract

When normal tissue and tumour samples are compared by microarray analysis, the biggest differences most often occur in the expression levels of genes that control cell proliferation. However, this difference is detected whenever mRNA samples that are taken from two cell populations with different proliferation rates are compared. Although the exact genes that comprise this 'proliferation signature' often differ, they are almost always genes that are involved in the fundamental process of cell proliferation. Can the proliferation signature be used to improve our understanding of the cell cycle and cancer pathogenesis, as well as being used as a biomarker for cancer diagnosis and prognosis?

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16491069     DOI: 10.1038/nrc1802

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  232 in total

1.  Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.

Authors:  Dung-Tsa Chen; Ying-Lin Hsu; William J Fulp; Domenico Coppola; Eric B Haura; Timothy J Yeatman; W Douglas Cress
Journal:  J Natl Cancer Inst       Date:  2011-12-08       Impact factor: 13.506

2.  Global mitotic phosphorylation of C2H2 zinc finger protein linker peptides.

Authors:  Raed Rizkallah; Karen E Alexander; Myra M Hurt
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

3.  A multi-gene transcriptional profiling approach to the discovery of cell signature markers.

Authors:  Youichiro Wada; Dan Li; Anne Merley; Andrew Zukauskas; William C Aird; Harold F Dvorak; Shou-Ching Shih
Journal:  Cytotechnology       Date:  2010-10-23       Impact factor: 2.058

4.  Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.

Authors:  Matthew D Wilkerson; Xiaoying Yin; Katherine A Hoadley; Yufeng Liu; Michele C Hayward; Christopher R Cabanski; Kenneth Muldrew; C Ryan Miller; Scott H Randell; Mark A Socinski; Alden M Parsons; William K Funkhouser; Carrie B Lee; Patrick J Roberts; Leigh Thorne; Philip S Bernard; Charles M Perou; D Neil Hayes
Journal:  Clin Cancer Res       Date:  2010-07-19       Impact factor: 12.531

5.  MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.

Authors:  Einas M Yousef; Daniela Furrer; David L Laperriere; Muhammad R Tahir; Sylvie Mader; Caroline Diorio; Louis A Gaboury
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

6.  Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.

Authors:  Andrea Piunti; Rintaro Hashizume; Marc A Morgan; Elizabeth T Bartom; Craig M Horbinski; Stacy A Marshall; Emily J Rendleman; Quanhong Ma; Yoh-Hei Takahashi; Ashley R Woodfin; Alexander V Misharin; Nebiyu A Abshiru; Rishi R Lulla; Amanda M Saratsis; Neil L Kelleher; C David James; Ali Shilatifard
Journal:  Nat Med       Date:  2017-02-27       Impact factor: 53.440

Review 7.  To best measure cell proliferation in samples from the intestine.

Authors:  D Alferez; R A Goodlad
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

8.  The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition.

Authors:  Donato Tedesco; Jianhuan Zhang; Lan Trinh; Guita Lalehzadeh; Rene Meisner; Ken D Yamaguchi; Daniel L Ruderman; Harald Dinter; Deborah A Zajchowski
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

9.  Wnt signaling potentiates nevogenesis.

Authors:  Jeff S Pawlikowski; Tony McBryan; John van Tuyn; Mark E Drotar; Rachael N Hewitt; Andrea B Maier; Ayala King; Karen Blyth; Hong Wu; Peter D Adams
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

10.  Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.

Authors:  Xin-Yan Lu; Yaojuan Lu; Yi-Jue Zhao; Kim Jaeweon; Jason Kang; Li Xiao-Nan; Gouqing Ge; Rene Meyer; Laszlo Perlaky; John Hicks; Murali Chintagumpala; Wei-Wen Cai; Marc Ladanyi; Richard Gorlick; Ching C Lau; Debananda Pati; Michael Sheldon; Pulivarthi H Rao
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.